Management of Acute Ischaemic Stroke with add-on homoeopathy

Functional recovery assessment of persons with Acute Ischaemic stroke with homoeopathic intervention as an add-on to the standard treatment – A double blind randomised controlled trial - AIS-HOM

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057611

Enrollment

200

Registered

2023-09-14

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I63- Cerebral infarction

Interventions

Intervention1: Individualised homoeopathic medicines as an adjuvant to Allopathy(Arnica montana, Bothrops lanciolatus, Lathyrus sativus, Causticum, Gelsemium sempervirens, Plumbum metallicum, Baryta c

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases of any gender, more than 18 years of age, diagnosed with Acute Ischemic stroke [(ICD-11) 8B11: Cerebral ischaemic stroke] having symptoms for >6 hours to 7 days, on the basis of neurological clinical evaluation and neuro imaging. 2. Acute AIS patients with a history of AIS episode with 90% recovery of residual effects of previous episode. 3. Modified Rankin Scale (mRS) score from 2 to 5. 4. Written Informed consent from the patient.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating females. 2. Minor or rapidly improving stroke symptoms with complete recovery within 6 hours. 3. Cases of haemorrhagic stroke (subarachnoid haemorrhage, venous infarct), Transient Ischemic Attack (TIA). 4. Intraspinal surgery, serious head trauma (history or as a result of present episode of AIS). 5. Having previously diagnosed or clinically established disorders like recrudescence, migraine aura, seizures, peripheral vertigo and dizziness or Multiple sclerosis (MS) which may mimic AIS. 6. Neoplasia and other intracranial space-occupying lesions. 7. Severe, advanced cases of uncontrolled systemic diseases like cardiovascular, endocrinal, renal diseases, metabolic abnormalities like hyponatremia, hypocalcemia, hypoglycemia, uremia, or other disorders.

Design outcomes

Primary

Measure	Time frame
Assessment of functional recovery through Modified Rankin Scale (at baseline, 3 months, 6 months)and total & individual domain scores of Stroke Impact Scale questionnaire (at baseline & monthly follow ups)Timepoint: At baseline, 3 months, 6 months & monthly follow ups	—

Secondary

Measure	Time frame
Assessment of overall clinical improvement through Measure Yourself Medical Outcome Profile 2 (MYMOP2)Timepoint: Biweekly follow up	—

Countries

India

Contacts

Public ContactDr Vasundhara Aggarwal

Central Council for Research in Homoeopathy

dr.harleenkaur@gmail.com9818709729

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026